You're in luck if you're looking for a list of biotech stocks you can purchase. Below is a complete list of publicly traded businesses involved in biotech research and development. Incyte Corporation, Vertex Pharmaceuticals Inc., Anixa Biosciences, and Pitolisant are a few of these businesses.
CRISPR Therapeutics is a biotech business dedicated to creating CRISPR/Cas9-based medicines. The firm offers several treatment programs, two intended to prevent and treat hemoglobinopathies and type 1 diabetes. Vertex Pharmaceuticals and researchers are working to create therapies for beta-thalassemia and type 1 myotonic dystrophy.
CRISPR Therapeutics has succeeded with its sickle cell program, and management just disclosed that a new product candidate is currently undergoing clinical testing for transfusion-dependent beta-thalassemia. Patients with beta-thalassemia would experience less hemolysis and anemia due to this treatment, enhancing their general health.
International biopharmaceutical business Incyte Corporation. The corporation, headquartered in Wilmington, Delaware, produces drugs for various therapeutic uses. Jakafi, the company's best-selling medication, is approved to treat acute graft-versus-host disease that is steroid-refractory. Pemigatinib, an investigational treatment for cholangiocarcinoma, is one of the additional products in development.
Incyte made $813 million in total sales as of the third quarter. Jakafi generates 80% of the business's income. The medication is licensed to treat polycythemia vera, intermediate-risk myelofibrosis, and acute marrow-versus-host steroid-refractory disease. Sales for the fourth quarter were $466 million for Jakafi.
Twenty-one molecules are currently under development by Incyte. These six substances are all undergoing clinical testing. Several substances are also undergoing advanced testing.
Anixa Biosciences is a biotechnology business with its main office in San Jose, California. The company's clever small widgets are used in the diagnostics, cancer, and vaccinations industries. ITUS Corporation was its last name. The business changed its name to Anixa Biosciences in October 2018.
The most remarkable achievement of Anixa is creating an innovative immunotherapy medicine based on CAR-T cells. In addition to its most recent project, the company has a strong portfolio of reliable vaccines and other potential infectious disease agents. Some of their more esoteric products include a revolutionary vaccination for triple-negative breast cancer, a preventative ovarian cancer vaccine, and numerous small compounds for various inherited metabolic illnesses.
The business creates antibody-drug conjugates (ADCs) for solid and hematological cancers. They deploy pyrrolobenzodiazepine-based warheads together with monoclonal antibodies that specifically target tumor antigens. The PBD-based ADCs developed by ADC Therapeutics include ADCT-601, camidanlumab tesirine, and loncastuximab tesirine.
Patients with newly diagnosed diffuse large B-cell lymphoma participate in a phase 2 trial for the primary program from ADC Therapeutics, loncastuximab terrine. The business carries out numerous tests with the medicine and other substances in addition to treating patients. Its second medication, camidanlumab tesirine, targets CD25, a protein found on the cancer cell membrane that promotes the growth of numerous cancer types.
A brand-new drug called pitolisant is used to treat cataplexy in narcoleptic patients. It has been lauded as the first FDA-approved, non-scheduled medication for the illness. The drug is currently being assessed for more general uses, such as treating pediatric narcolepsy or the more prevalent idiopathic hypersomnia.
Pitolisant belongs to the group of drugs known as H3 blockers. The business that created Bioprojet is already selling the medication in other nations. The European Medicines Agency approved Pitolisant in 2016. (EMA).
Although its effects aren't as strong as those of other comparable medications, its Kd value of 50+-4 pM is impressive. Additionally, pitolisant does not exhibit any amphetamine-like characteristics, in contrast to other H3 agonists.
A biotechnology business called Vertex Pharmaceuticals creates small-molecule medications for severe disorders. The company's medicines treat inflammatory bowel disease, cancer, neurological disorders, and infectious diseases. Boston, Massachusetts, serves as its administrative center. It has locations throughout Latin America, Europe, and North America.
In 1989, Vertex was established. Its business at the time was centered on viral infections and inflammatory illnesses. It created protease inhibitors in the 1990s to treat HIV infection.
Vertex had a dozen pharmaceutical medicines under development by 2002. They wanted to create a potent drug discovery engine. They employed Navia, a professional in logical medication design.
